ASCO

GSK Oncology Pipeline: Showcasing Long-Term Outcomes at ASCO and EHA 2026

By BiotechReality Business Intelligence Desk
26 May 2026

GSK is set to demonstrate the strength of its oncology pipeline at major 2026 congresses, highlighting long-term outcomes for Jemperli and Blenrep alongside new GIST data.

Tag: ASCO

GSK Oncology Pipeline: Showcasing Long-Term Outcomes at ASCO and EHA 2026

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement